Major Publications in the Critical Care Pharmacotherapy Literature: 2023.
Journal
Critical care explorations
ISSN: 2639-8028
Titre abrégé: Crit Care Explor
Pays: United States
ID NLM: 101746347
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
3
10
2024
Statut:
epublish
Résumé
We aimed to summarize the most significant and impactful publications describing the pharmacotherapeutic care of critically ill patients in 2023. PubMed/MEDLINE and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update. Randomized controlled trials and prospective studies of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints published between January 1, 2023, and December 31, 2023, were eligible for inclusion in this article. Articles from a systematic search and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update were included. An a priori defined three-round modified Delphi process was employed to achieve consensus on the most impactful publications based on the following considerations: 1) overall contribution to scientific knowledge and 2) novelty to the literature. The systematic search and Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update returned a total of 1202 articles, of which 1164 were excluded. The remaining 38 articles underwent a three-round modified Delphi process. In each round, articles were independently scored based on overall contribution to scientific knowledge and novelty to the literature. Included articles are summarized and their impact discussed. Article topics included hydrocortisone for severe community-acquired pneumonia, inhaled amikacin for prevention of ventilator-associated pneumonia, methylene blue for septic shock, restrictive vs. liberal fluid management for sepsis-induced hypotension, andexanet alfa for major bleeding associated with factor Xa inhibitors, and early administration of four-factor prothrombin complex concentrate in patients with trauma at risk for massive transfusion. This review provides a summary and perspective on the potential impact of the most relevant articles in 2023 describing advances in the pharmacotherapeutic care of critically ill patients.
Identifiants
pubmed: 39360775
doi: 10.1097/CCE.0000000000001162
pii: 02107256-202410000-00007
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1162Informations de copyright
Copyright © 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.
Déclaration de conflit d'intérêts
Dr. Makic is an editor of critical care texts for Elsevier and chair of clinical practice alerts. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Références
Tsutsumi Y, Tsuchiya A, Kawahara T: Publication hyper-inflation in the field of intensive care. Intensive Care Med 2023; 49:706–707
Hsu N, Liao C, Hsu C: Proportions and trends of critical care trials in leading general medical journals, 1970-2022. Crit Care 2023; 27:375
Wyatt JC, Sullivan F: Keeping up: Learning in the workplace. BMJ 2005; 331:1129–1132
Maggio LA, Artino AR Jr: Staying up to date and managing information overload. J Grad Med Educ 2018; 10:597–598
Kamtchum-Tatuene J, Zafack JG: Keeping up with the medical literature: Why, how, and when? Stroke 2021; 52:e746–e748
Turck CJ, Frazee E, Kram B, et al.; Critical Care Pharmacotherapy Literature Update Group: Major publications in the critical care pharmacotherapy literature: February 2012 through February 2013. Am J Health Syst Pharm 2014; 71:68–77
Rech MA, Day SA, Kast JM, et al.; Critical Care Pharmacotherapy Literature Update Group: Major publications in the critical care pharmacotherapy literature: January-December 2013. Am J Health Syst Pharm 2015; 72:224–236
Day SA, Cucci M, Droege ME, et al.: Major publications in the critical care pharmacotherapy literature: January-December 2014. Am J Health Syst Pharm 2015; 72:1974–1985
Wong A, Erdman M, Hammond DA, et al.: Major publications in the critical care pharmacotherapy literature in 2015. Am J Health Syst Pharm 2017; 74:295–311
Horner D, Altshuler D, Droege C, et al.: Major publications in the critical care pharmacotherapy literature: January-December 2016. J Crit Care 2018; 43:327–339
Hammond DA, Baumgartner L, Cooper C, et al.: Major publications in the critical care pharmacotherapy literature: January-December 2017. J Crit Care 2018; 45:239–246
Sikora Newsome A, Bissell BD, Burry LD, et al.: Major publications in the critical care pharmacotherapy literature in 2018. J Crit Care 2019; 52:200–207
Smith Condeni M, Basting AT, Cotello PG, et al.: Major publications in the critical care pharmacotherapy literature: 2019. J Crit Care 2021; 62:197–205
Bissell BD, Campbell J, Collins R, et al.: Major publications in the critical care pharmacotherapy literature: 2020. Crit Care Explor 2021; 3:e0590
Wieruszewski PM, Brickett LM, Dayal L, et al.: Major publications in the critical care pharmacotherapy literature: 2021. Crit Care Explor 2022; 4:e0823
Gurnani PK, Barlow B, Boling B, et al.: Major publications in the critical care pharmacotherapy literature: 2022. Crit Care Explor 2023; 5:e0981
Dequin P, Meziani F, Quenot J, et al.; CRICS-TriGGERSep Network: Hydrocortisone in severe community-acquired pneumonia. N Engl J Med 2023; 388:1931–1941
Torres A, Sibila O, Ferrer M, et al.: Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. JAMA 2015; 313:677–686
Nair GB, Niederman MS: Updates on community acquired pneumonia management in the ICU. Pharmacol Ther 2021; 217:107663
Briel M, Spoorenberg SMC, Snijders D, et al.; Ovidius Study Group: Corticosteroids in patients hospitalized with community-acquired pneumonia: Systematic review and individual patient data metaanalysis. Clin Infect Dis 2018; 66:346–354
Stern A, Skalsky K, Avni T, et al.: Corticosteroids for pneumonia. Cochrane Database Syst Rev 2017; 12:CD007720
Chaudhuri D, Nei AM, Rochwerg B, et al.: 2024 focused update: Guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Crit Care Med 2024; 52:e219–e233
Magill SS, O’Leary E, Janelle SJ, et al.; Emerging Infections Program Hospital Prevalence Survey Team: Changes in prevalence of health care-associated infections in US hospitals. N Engl J Med 2018; 379:1732–1744
Wang Y, Eldridge N, Metersky ML, et al.: National trends in patient safety for four common conditions, 2005-2011. N Engl J Med 2014; 370:341–351
Kalil AC, Metersky ML, Klompas M, et al.: Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61–e111
Rouby JJ, Poete P, de Lassale EM, et al.: Prevention of gram negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Histologic and bacteriologic study. Intensive Care Med 1994; 20:187–192
Wood GC, Boucher BA, Croce MA, et al.: Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Pharmacotherapy 2002; 22:972–982
Claridge JA, Edwards NM, Swanson J, et al.: Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: Results of a double-blind randomized study. Surg Infect (Larchmt) 2007; 8:83–90
Karvouniaris M, Makris D, Zygoulis P, et al.: Nebulised colistin for ventilator-associated pneumonia prevention. Eur Respir J 2015; 46:1732–1739
Lode H, Hoffken G, Kemmerich B, et al.: Systemic and endotracheal antibiotic prophylaxis of nosocomial pneumonia in ICU. Intensive Care Med 1992; 18:S24–S27
Klompas M, Branson R, Cawcutt K, et al.: Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol 2022; 43:687–713
Shapiro NI, Douglas IS, Brower RG, et al.; National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network: Early restrictive or liberal fluid management for sepsis-induced hypotension. N Engl J Med 2023; 388:499–510
Rhee C, Dantes R, Epstein L, et al.; CDC Prevention Epicenter Program: Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 2017; 318:1241–1249
Fleischmann-Struzek C, Mellhammar L, Rose N, et al.: Incidence and mortality of hospital- and ICU-treated sepsis: Results from an updated and expanded systematic review and meta-analysis. Intensive Care Med 2020; 46:1552–1562
Rivers E, Nguyen B, Havstad S, et al.; Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368–1377
Evans L, Rhodes A, Alhazzani W, et al.: Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Crit Care Med 2021; 49:e1063–e1143
Kelm DJ, Perrin JT, Cartin-Ceba R, et al.: Fluid overload in patients with severe sepsis and septic shock treated with early goal-directed therapy is associated with increased acute need for fluid-related medical interventions and hospital death. Shock 2015; 43:68–73
Hernandez G, Ospina-Tascon GA, Damiani LP, et al.; The ANDROMEDA SHOCK Investigators and the Latin America Intensive Care Network (LIVEN): Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: The ANDROMEDA-SHOCK randomized clinical trial. JAMA 2019; 321:654–664
Meyhoff TS, Hjortrup PB, Wetterslev J, et al.; CLASSIC Trial Group: Restriction of intravenous fluid in ICU patients with septic shock. N Engl J Med 2022; 386:2459–2470
Ibarra-Estrada M, Kattan E, Aguilera-Gonzalez P, et al.: Early adjunctive methylene blue in patients with septic shock: A randomized controlled trial. Crit Care 2023; 27:110
Russell JA, Walley KR, Singer J, et al.; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877–887
Annane D, Renault A, Brun-Buisson C, et al.; CRICS-TRIGGERSEP Network: Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018; 378:809–818
Sacha GL, Lam SW, Wang L, et al.: Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock. Crit Care Med 2022; 50:614–623
Hammond DA, Ficek OA, Painter JT, et al.: Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy 2018; 38:531–538
Ragoonanan D, Allen B, Cannon C, et al.: Comparison of early versus late initiation of hydrocortisone in patients with septic shock in the ICU setting. Ann Pharmacother 2022; 56:264–270
Lopez A, Lorente JA, Steingrub J, et al.: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21–30
Memis D, Karamanlioglu B, Yuksel M, et al.: The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care 2022; 30:755–762
Kirov MY, Evgenov OV, Evgenov NV, et al.: Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study. Crit Care Med 2001; 29:1860–1867
Bouzat P, Charbit J, Abback P, et al.; PROCOAG Study Group: Efficacy and safety of early administration of 4-factor prothrombin complex concentrate in patients with trauma at risk of massive transfusion: The PROCOAG randomized clinical trial. JAMA 2023; 329:1367–1375
Moore FA, Moore EE, Sauaia A: Blood transfusion. An independent risk factor for postinjury multiple organ failure. Arch Surg 1997; 132:620–624; discussion 624–625
Zeeshan M, Hamidi M, Feinstein AJ, et al.: Four-factor prothrombin complex concentrate is associated with improved survival in trauma-related hemorrhage: A nationwide propensity-matched analysis. J Trauma Acute Care Surg 2019; 87:274–281
Jehan F, Aziz H, O’Keeffe T, et al.: The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: A propensity matched analysis. J Trauma Acute Care Surg 2018; 85:18–24
Hannadjas I, James A, Davenport R, et al.: Prothrombin complex concentrate (PCC) for treatment of trauma-induced coagulopathy: Systematic review and meta-analyses. Crit Care 2023; 27:422
Cannon JW, Khan MA, Raja AS, et al.: Damage control resuscitation in patients with severe traumatic hemorrhage: A practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg 2017; 82:605–617
Rossaint R, Afshari A, Bouillon B, et al.: The European guideline on management of major bleeding and coagulopathy following trauma: Sixth edition. Crit Care 2023; 27:80
Milling TJ Jr, Middledorp S, Xu L, et al.: Final study report of andexanet alfa for major bleeding with factor Xa inhibitors. Circulation 2023; 147:1026–1038
Connolly SJ, Milling TJ Jr, Eikelboom JW: Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 65:279–280
Connolly SJ, Crowther M, Eikelboom JW, et al.; ANNEXA-4 Investigators: Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380:1326–1335
Connolly SJ, Sharma M, Cohen AT, et al.; ANNEXA-I Investigators: Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med 2024; 390:1745–1755